A phase 1 placebo-controlled, single ascending dose clinical study of CK-271 in healthy adults
Latest Information Update: 02 Mar 2021
At a glance
- Drugs CK 271 (Primary)
- Indications Hypertrophic cardiomyopathy
- Focus Adverse reactions
- 25 Feb 2021 Status changed from recruiting to completed, according to a Cytokinetics media release.
- 04 Nov 2020 According to a Cytokinetics media release, the study is expected to be completed by the end of 2020.
- 23 Sep 2020 According to a Cytokinetics media release, first participant has been dosed in this trial.